Biome reports record quarterly sales revenue for Q2 FY25

Biome Australia Limited (ASX: BIO) has reported impressive financial results for the second quarter of fiscal year 2025 (Q2 FY25).

Financial Highlights:

• Biome achieved a new record in quarterly sales revenue of approximately $4.6 million for Q2 FY25
• Sales revenue for the first half of FY25 (H1) reached about $8.9 million, representing a 48.3% increase compared to H1 FY24
• The company has maintained a strong compound annual growth rate (CAGR) of 70.5% for the three years ending December 31, 2024
• Q2 sales revenue translates to an annualised run rate (ARR) of approximately $18.4 million

Biome Australia implemented several key strategies to boost revenue in 2024.

Biome grew its distribution points in Australia to over 5,000 locations, including pharmacies and practitioners. This increased the company’s market reach and accessibility to customers.

After a two-month testing period, Biome successfully entered the Canadian market, engaging a practitioner education consultant in Ontario to help penetrate the market. The company also received Health Canada approval for 12 of its 17 products.

Biome signed an agreement to add a condition-specific live biotherapeutic product, Biome Cholesterol Probiotic, to its Activated Probiotics product range. This new product targets lowering cholesterol levels and was released in the second half of the calendar year. Biome continued to strengthen its presence in Australia, with Activated Probiotics becoming the number two brand in total revenue within the practitioner-only category and the number one for growth.

The company achieved a 75% increase in same-store sales in the Australian pharmacy channel, showing strong organic growth in its primary distribution channel.

Biome’s gross margin exceeded 60%, up from 59% in the previous year, improving profitability alongside revenue growth.

Biome expects continued strong growth throughout the remainder of FY25, with the second half traditionally being their most substantial sales period. The company has achieved positive EBITDA over the last three quarters and recently released “Vision 27,” a three-year strategic plan aiming for cumulative sales of $85 million for FY25-27, requiring a CAGR of approximately 45%. With the brand launch of Activated Therapeutics and the higher growth expected in international markets, we believe Biome is on track for a very strong H2 outcome.

Overall, this announcement is another significant positive result for Biome Australia. It demonstrates its strong growth trajectory and stable management, which sets the platform for future success.

Please follow the link below to read the full announcement.